SCHEMBL6751990

SCHEMBL6751990

O=NN(CCO)C(=O)NCCO

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.60
MEN1 O00255 2/20 0.60
KMT2A Q03164 2/20 0.60
BLM P54132 2/20 0.60
PMP22 Q01453 2/20 0.60
ABCB11 O95342 1/20 0.60
GSR P00390 1/20 0.60
TSHR P16473 1/20 0.60
HTT P42858 1/20 0.60
USP2 O75604 1/20 0.37
MAPT P10636 1/20 0.37
ADRA2A P08913 2/20 0.36
PDE4A P27815 1/20 0.36
ADRA1A P35348 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.33
LMNA P02545 1/20 0.32
NFKB1 P19838 1/20 0.32
NTRK2 Q16620 1/20 0.32
CHRNB2 P17787 1/20 0.31
CHRNB4 P30926 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20906025 0.86 ALDH1A1 (0.82) ALDH1A1MEN1KMT2ABLMPMP22
Elmustine SCHEMBL93476 0.86 ALDH1A1 (0.82) ALDH1A1MEN1KMT2ABLMPMP22
SCHEMBL25859798 0.75 ALDH1A1 (0.56) ALDH1A1MEN1KMT2ABLMPMP22
Carmustine SCHEMBL2047318 0.75 ALDH1A1 (1.00) ALDH1A1MEN1KMT2ABLMPMP22
SCHEMBL19351408 0.75 ALDH1A1 (0.56) ALDH1A1MEN1KMT2ABLMPMP22
Carmustine SCHEMBL4503 0.75 ALDH1A1 (1.00) ALDH1A1MEN1KMT2ABLMPMP22
SCHEMBL12266130 0.75 MEN1 (0.41) ALDH1A1MEN1KMT2ABLMPMP22
SCHEMBL691955 0.75 ALDH1A1 (0.41) ALDH1A1MEN1KMT2ABLMPMP22
SCHEMBL25860611 0.72 ALDH1A1 (0.53) ALDH1A1MEN1KMT2ABLMPMP22
SCHEMBL1447307 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2536483-B1 SOLVENT TREATMENT PROCESS COMMW SCIENT IND RES ORG (AU) 2017-05-31 EP disclosed
US-20130053614-A1 SOLVENT TREATMENT PROCESS COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH OR (AU) 2013-02-28 US disclosed
WO-2004056372-A1 USE OF AGLYCON PROTOPANAXADIOL IN CANCER THERAPY PANAGIN PHARMACEUTICALS INC. (CA) 2004-07-08 WO disclosed
WO-2004056379-A1 SAPONINS AND SAPOGENINS FOR USE IN COMBINATION THERAPY FOR CANCER PANAGIN PHARMACEUTICALS INC. (CA) 2004-07-08 WO disclosed
WO-2004056371-A1 USE OF AGLYCON PROTOPANAXATRIOL IN CANCER THERAPY PANAGIN PHARMACEUTICALS INC. (CA) 2004-07-08 WO disclosed